EcoR1 Capital, LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001587114
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q1 2026 · 29 positions · Total reported value $2.12B · Top-10 concentration 90.0% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 47.5% · 9 new · 4 cut · 6 exited
Active Share (vs S&P 500): 99.8% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -3.0% · vs SPY -5.1% · Prev Value $1.95B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): +0.9% · vs SPY -1.2% · Latest Value $2.11B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q1 2026 13F filing, EcoR1 Capital, LLC disclosed 29 equity positions with a combined reported value of $2.12B. The filing implies a focused portfolio: its ten largest positions account for 90.0% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q1 2026 were ZYME ($575.18M), ANAB ($437.03M), JAZZ ($322.61M). By sector, the heaviest allocations are Health Care 89.4%, Financials 0.1%. Versus the prior quarter, allocation shifted toward Health Care (+5.5pp) and away from Other (-5.6pp).
Versus the prior quarter, EcoR1 Capital, LLC opened 9 new positions, trimmed 4 and fully exited 6, a turnover rate of 47.5% of positions. The portfolio's overlap with the prior quarter was 50% of names.
The largest new positions opened in Q1 2026 were AKTS ($86.31M), RLAY ($18.95M), ERAS ($14.56M).
Of the 6 positions fully exited versus the prior quarter, the largest were IMNM ($61.34M), GPCR ($23.26M), PCVX ($20.76M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q1 2026)
Fully Exited (vs previous quarter)
- IMNM IMMUNOME INC · prev qtr: $61.34M
- GPCR STRUCTURE THERAPEUTICS INC · prev qtr: $23.26M
- PCVX VAXCYTE INC · prev qtr: $20.76M
- AQST AQUESTIVE THERAPEUTICS INC · prev qtr: $16.96M
- VYGR VOYAGER THERAPEUTICS INC · prev qtr: $15.73M
- MNKD MANNKIND CORP · prev qtr: $9.41M
- NUVBWS NUVATION BIO INC · prev qtr: $8.63M
- EOLS EVOLUS INC · prev qtr: $4.49M
Insider Transactions (Form 4)
Latest EcoR1 Capital, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-05-07 | Buy | Atara Biotherapeutics, Inc. | 507,407 | $9.35 | SEC filing |
| 2026-04-20 | Sell | First Tracks Biotherapeutics, Inc. | 4,705,575 | $13.81 | SEC filing |
Fund Profile
EcoR1 Capital, LLC, based in San Francisco, CA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 31 positions worth $1.95B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: SAN FRANCISCO, CA, United States
- SEC registration: 801-100470 (status: Approved), registered 2015-07-02
- Regulatory AUM (Form ADV): $3.42B as of 2026-03-30
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 3 private funds, of which 2 hedge funds
Portfolio Structure
- 31 positions · $1.95B reported value (Q2 2026)
- Top 10 holdings = 87.7% of reported value
- Largest position: ZYME (ZYMEWORKS INC) at 30.8%
- Average position size: $62.85M
Sector Tilt
- Health Care 97.3%
- Financials 0.1%
- (classified holdings cover 97% of value)
Quarterly Activity
- Q2 2026: 9 new, 2 added, 5 reduced, 7 exited
- 15 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
22.97M | $575.18M | 27.16% | Hold | |
| 2 |
|
7.88M | $437.03M | 20.63% | Hold | |
| 3 |
|
1.71M | $322.61M | 15.23% | Hold | |
| 4 |
|
4.29M | $155.74M | 7.35% | Hold | |
| 5 |
|
4.82M | $86.31M | 4.08% | New | |
| 6 |
|
6.73M | $85.25M | 4.03% | Hold | |
| 7 |
|
1.10M | $74.58M | 3.52% | Add | |
| 8 |
|
1.39M | $66.09M | 3.12% | Hold | |
| 9 |
|
2.17M | $53.60M | 2.53% | Add | |
| 10 |
|
1.67M | $50.01M | 2.36% | Hold | |
| 11 |
|
2.18M | $26.33M | 1.24% | Add | |
| 12 |
|
1.27M | $25.63M | 1.21% | Hold | |
| 13 |
|
2.82M | $25.27M | 1.19% | Hold | |
| 14 |
|
777.00K | $23.19M | 1.09% | Reduce | |
| 15 |
|
1.90M | $18.95M | 0.90% | New | |
| 16 |
|
410.80K | $16.32M | 0.77% | Reduce | |
| 17 |
|
789.50K | $15.43M | 0.73% | Hold | |
| 18 |
|
900.00K | $14.56M | 0.69% | New | |
| 19 |
|
732.61K | $7.75M | 0.37% | New | |
| 20 |
|
1.00M | $7.65M | 0.36% | New | |
| 21 |
|
1.18M | $7.02M | 0.33% | New | |
| 22 |
|
625.00K | $6.94M | 0.33% | New | |
| 23 |
|
13.37M | $4.41M | 0.21% | Add | |
| 24 |
|
100.00K | $3.26M | 0.15% | New | |
| 25 |
|
947.05K | $3.24M | 0.15% | New | |
| 26 |
|
1.58M | $3.01M | 0.14% | Reduce | |
| 27 |
|
200.00K | $2.03M | 0.10% | New | |
| 28 |
|
99.59K | $471.07K | 0.02% | Reduce | |
| 29 |
|
4.44K | $129.45K | 0.01% | Hold | |
FAQ
What did EcoR1 Capital, LLC buy in 2026-Q1?
In its 2026-Q1 13F filing, EcoR1 Capital, LLC reported 29 equity positions worth $2.12B in aggregate; its largest disclosed positions were ZYME ($575.18M), ANAB ($437.03M), JAZZ ($322.61M).
How large is EcoR1 Capital, LLC's portfolio?
EcoR1 Capital, LLC reported $2.12B of long equity holdings across 29 positions as of 2026-Q1. Top-10 holdings account for 90.0% of reported value.
What is EcoR1 Capital, LLC's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.